The Competition and Consumer Commission of Singapore (“CCCS”) has granted conditional approval of Pathology Asia Holdings Pte. Ltd. (“PAH”)’s completed acquisition of Innovative Diagnostics Private Limited (“Innovative”) and Quest Laboratories Pte. Ltd. (“Quest”) (each a “Party” and collectively, the “Parties”) (the “Transaction”),after accepting commitments from PAH.

Both Innovative and Quest provide in-vitro diagnostic (“IVD”) tests in Singapore, which can be used to detect diseases or other conditions, as well as monitor a person’s health. PAH is part of TPG Capital, a global private investment firm founded in 1992.

Read the full media release here.